ReviewExpert review of vaccines2015
RNA-based drugs and vaccines.
Review in Expert review of vaccines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Engineered self-assembling hydrogel systems for advanced guided bone regeneration: structural optimization and biofunctional modulation.Journal of nanobiotechnology · 2025Review
- Nanomedicine innovations in colon and rectal cancer: advances in targeted drug and gene delivery systems.Medical oncology (Northwood, London, England) · 2025Review
- A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine.Reviews on recent clinical trials · 2024Review
- Research progress on non-protein-targeted drugs for cancer therapy.Journal of experimental & clinical cancer research : CR · 2023Review
- DoE-derived continuous and robust process for manufacturing of pharmaceutical-grade wide-range LNPs for RNA-vaccine/drug delivery.Scientific reports · 2022Article
- Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus.Environmental science and pollution research international · 2021Review
- MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2.Non-coding RNA · 2021Article
- A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies.Molecules (Basel, Switzerland) · 2019Review
- The CRISPR-Cas13a Gene-Editing System Induces Collateral Cleavage of RNA in Glioma Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Latest development on RNA-based drugs and vaccines.Future science OA · 2018Review
- Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside.Molecules (Basel, Switzerland) · 2016Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA-based approaches have provided novel alternatives for modern drug discovery. The application of RNA as therapeutic agents has, until recently, been hampered by issues related to poor delivery and stability, but chemical modifications and new delivery approaches have increased progress. Moreover, the discovery of the importance of RNA in gene regulation and gene silencing has revealed new drug targets, especially related to treatment of cancer and other diseases. Recent engineering of small molecules designed from RNA sequences to target miRNAs opens up new possibilities in drug development. Furthermore, RNA-based vaccines have been engineered applying RNA virus vectors and non-viral delivery for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.